CY1110801T1 - Μεθοδοι και συνθεσεις για την προληψη και θεραπεια της αναιμιας - Google Patents

Μεθοδοι και συνθεσεις για την προληψη και θεραπεια της αναιμιας

Info

Publication number
CY1110801T1
CY1110801T1 CY20101100863T CY101100863T CY1110801T1 CY 1110801 T1 CY1110801 T1 CY 1110801T1 CY 20101100863 T CY20101100863 T CY 20101100863T CY 101100863 T CY101100863 T CY 101100863T CY 1110801 T1 CY1110801 T1 CY 1110801T1
Authority
CY
Cyprus
Prior art keywords
methods
analogue
hematocrit
erythropoietin
compositions
Prior art date
Application number
CY20101100863T
Other languages
English (en)
Inventor
Joan C Egrie
Jeffrey K Browne
Steven G Elliott
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22651968&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110801(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1110801T1 publication Critical patent/CY1110801T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Αποκαλύπτονται μέθοδοι για την αύξηση και διατήρηση του αιματοκρίτη σε ένα θηλαστικό οι οποίες περιλαμβάνουν τη χορήγηση ενός υπεργλυκοζυλιωμένου αναλόγου της ερυθροποιητίνης. Ένα ανάλογο μπορεί να χορηγηθεί λιγότερο συχνά από μια ισοδύναμη γραμμομοριακή ποσότητα ανασυνδυασμένης ανθρώπινης ερυθροποιητίνης για να ληφθεί ένας συγκρίσιμος αιματοκρίτης στόχος και να θεραπευθεί η αναιμία. Εναλλακτικώς, μπορεί να χορηγηθεί μικρότερη γραμμομοριακή ποσότητα ενός υπεργλυκοζυλιωμένου αναλόγου της ερυθροποιητίνης για να ληφθεί ένας συγκρίσιμος αιματοκρίτης στόχος και να θεραπευθεί η αναιμία. Αποκαλύπτονται επίσης νέα υπεργλυκοζυλιωμένα ανάλογα ερυθροποιητίνης, μέθοδοι παρασκευή των αναλόγων και συνθέσεις που περιέχουν τα ανάλογα.
CY20101100863T 1998-10-23 2010-09-27 Μεθοδοι και συνθεσεις για την προληψη και θεραπεια της αναιμιας CY1110801T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17829298A 1998-10-23 1998-10-23
EP07004087A EP1813624B1 (en) 1998-10-23 1999-10-18 Methods and compositions for the prevention and treatment of anemia

Publications (1)

Publication Number Publication Date
CY1110801T1 true CY1110801T1 (el) 2015-06-10

Family

ID=22651968

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071100322T CY1107584T1 (el) 1998-10-23 2007-03-07 Μεθοδοι και συνθεσεις για την προληψη και θepαπεια της αναιμιας
CY20101100863T CY1110801T1 (el) 1998-10-23 2010-09-27 Μεθοδοι και συνθεσεις για την προληψη και θεραπεια της αναιμιας

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071100322T CY1107584T1 (el) 1998-10-23 2007-03-07 Μεθοδοι και συνθεσεις για την προληψη και θepαπεια της αναιμιας

Country Status (19)

Country Link
EP (2) EP1123313B2 (el)
JP (2) JP4809977B2 (el)
KR (1) KR20010075661A (el)
CN (2) CN1346369B (el)
AR (1) AR020848A1 (el)
AT (2) ATE355303T1 (el)
AU (1) AU774989B2 (el)
CA (1) CA2345882C (el)
CY (2) CY1107584T1 (el)
DE (2) DE69942680D1 (el)
DK (2) DK1123313T3 (el)
ES (2) ES2347884T3 (el)
HK (1) HK1040944B (el)
HU (1) HU228492B1 (el)
IL (2) IL142334A (el)
PT (2) PT1123313E (el)
SI (2) SI1123313T1 (el)
TW (1) TWI234583B (el)
WO (1) WO2000024893A2 (el)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
PT888385E (pt) 1996-03-14 2004-01-30 Genentech Inc Utilizacoes de gdnf e de receptores de gdnf
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
JP3660880B2 (ja) * 1999-05-07 2005-06-15 ジェネンテック・インコーポレーテッド 新規なチンパンジーエリスロポエチン（ｃｈｅｐｏ）ポリペプチドおよびこれをコードする核酸
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6555343B1 (en) 1999-05-07 2003-04-29 Genentech Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
PT1274728E (pt) * 2000-04-21 2008-06-20 Amgen Inc Métodos e composições para a prevenção e tratamento de anemia
PT1311285E (pt) 2000-05-15 2005-06-30 Hoffmann La Roche Composicao farmaceutica liquida contendo um derivado de eritropoietina
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
KR20060019501A (ko) * 2002-07-01 2006-03-03 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 응답 세포, 조직 및 기관을 보호, 회복 및 향상시키기위한 재조합 조직 보호 사이토카인 및 이를 코딩하는 핵산
AU2003246486A1 (en) * 2002-07-19 2004-02-09 Cangene Corporation Pegylated erythropoietic compounds
EP1644363B1 (en) 2003-05-30 2012-02-22 Gemin X Pharmaceuticals Canada Inc. Triheterocyclic compounds, compositions, and methods for treating cancer
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US20090029907A1 (en) * 2005-05-24 2009-01-29 Avesthagen Limited Recombinant Method for Production of an Erythropoiesis Stimulating Protein
EP1957637B1 (en) 2005-12-08 2013-08-14 Amgen, Inc. Improved host cells and culture methods
WO2007070315A2 (en) 2005-12-08 2007-06-21 Amgen Inc. Improved production of glycoproteins using manganese
EP2057472B1 (en) 2006-07-21 2013-11-13 Amgen Inc. Method of detecting and/ or measuring hepcidin in a sample
US8383114B2 (en) 2007-09-27 2013-02-26 Amgen Inc. Pharmaceutical formulations
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
ES2487846T3 (es) 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
CN101323630B (zh) * 2008-07-25 2013-06-05 中国科学院上海有机化学研究所 一种过渡金属络合物、合成方法及其用途
WO2010056981A2 (en) 2008-11-13 2010-05-20 Massachusetts General Hospital Methods and compositions for regulating iron homeostasis by modulation bmp-6
EP3009447B1 (en) 2009-07-24 2018-06-06 Dr. Reddy's Laboratories, Ltd. Production of erythropoiesis stimulating protein using metal ions
AU2010308030B2 (en) 2009-10-12 2014-05-29 Pfizer Inc. Cancer treatment
WO2011050333A1 (en) 2009-10-23 2011-04-28 Amgen Inc. Vial adapter and system
ES2545411T5 (es) 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
MX341790B (es) 2011-03-31 2016-09-02 Amgen Inc Adaptador de viales y sistema.
WO2012145183A2 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
AU2012245231B2 (en) 2011-04-20 2016-10-13 Amgen Inc. Autoinjector apparatus
CN103930142B (zh) 2011-10-14 2016-12-14 安姆根有限公司 注射器和装配方法
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
JP6768501B2 (ja) 2013-03-15 2020-10-14 アムゲン・インコーポレーテッド 薬物カセット、自動注入機、および自動注入機システム
CA2904725C (en) 2013-03-15 2022-04-12 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
DK2968503T3 (en) 2013-03-15 2018-12-03 Intrinsic Lifesciences Llc ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
WO2014149357A1 (en) 2013-03-22 2014-09-25 Amgen Inc. Injector and method of assembly
PL3060275T3 (pl) 2013-10-24 2019-12-31 Amgen Inc. Wstrzykiwacz i sposób montażu
EP3060281B1 (en) 2013-10-24 2019-01-30 Amgen Inc. Drug delivery system with temperature-sensitive control
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
AU2015256082C1 (en) 2014-05-07 2020-09-10 Amgen Inc. Autoinjector with shock reducing elements
CN112237662B (zh) 2014-06-03 2022-10-21 安姆根有限公司 药物递送***和使用方法
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AU2015332557B2 (en) 2014-10-14 2020-05-14 Amgen Inc. Drug injection device with visual and audio indicators
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
JP6716566B2 (ja) 2014-12-19 2020-07-01 アムジエン・インコーポレーテツド 近接センサ付き薬物送達装置
LT3240801T (lt) 2014-12-31 2021-02-25 Checkmate Pharmaceuticals, Inc. Kombinuota navikų imunoterapija
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
EP3429663B1 (en) 2016-03-15 2020-07-15 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
US11202818B2 (en) 2016-09-14 2021-12-21 President And Fellows Of Harvard College Methods and compositions for modulating erythropoiesis
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
EP3592403A1 (en) 2017-03-06 2020-01-15 Amgen Inc. Drug delivery device with activation prevention feature
IL268478B2 (en) 2017-03-07 2023-10-01 Amgen Inc Inserting a needle using super pressure
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for a drug delivery device
CN110446499A (zh) 2017-03-20 2019-11-12 豪夫迈·罗氏有限公司 一种体外糖基工程化红细胞生成刺激蛋白的方法
EP4241807A3 (en) 2017-03-28 2023-10-11 Amgen Inc. Plunger rod and syringe assembly system and method
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
AU2018282077B2 (en) 2017-06-08 2023-11-23 Amgen Inc. Torque driven drug delivery device
US11541183B2 (en) 2017-06-22 2023-01-03 Amgen Inc. Device activation impact/shock reduction
JP7475860B2 (ja) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
ES2972207T3 (es) 2017-07-14 2024-06-11 Amgen Inc Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
EP4085942A1 (en) 2017-07-25 2022-11-09 Amgen Inc. Drug delivery device with gear module and related method of assembly
EP3658206A1 (en) 2017-07-25 2020-06-03 Amgen Inc. Drug delivery device with container access system and related method of assembly
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
IL272636B1 (en) 2017-10-06 2024-06-01 Amgen Inc Drug delivery device with combination assembly and related assembly method
WO2019074579A1 (en) 2017-10-09 2019-04-18 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF
EP3703778A1 (en) 2017-11-03 2020-09-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
SG11202002966QA (en) 2017-11-10 2020-05-28 Amgen Inc Plungers for drug delivery devices
SG11202002772VA (en) 2017-11-16 2020-04-29 Amgen Inc Autoinjector with stall and end point detection
IL273638B1 (en) 2017-11-16 2024-06-01 Amgen Inc Door lock mechanism for drug delivery device
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US12042645B2 (en) 2018-07-24 2024-07-23 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
WO2020028009A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
CA3110371A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
EP3860685A1 (en) 2018-10-02 2021-08-11 Amgen Inc. Injection systems for drug delivery with internal force transmission
EP3860686A1 (en) 2018-10-05 2021-08-11 Amgen Inc. Drug delivery device having dose indicator
MA53912A (fr) 2018-10-15 2022-01-19 Amgen Inc Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
CA3109988A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
CA3113076A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MX2021012557A (es) 2019-04-24 2021-11-12 Amgen Inc Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
US20240208680A1 (en) 2021-05-21 2024-06-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2023209074A1 (en) 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
WO2024094457A1 (en) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
KR100221066B1 (ko) * 1989-10-13 1999-10-01 스튜어트 엘.왓트 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
ZA946122B (en) * 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US5541458A (en) * 1994-11-14 1996-07-30 Hewlett-Packard Company Power supply for timed residual power after turn off
DE19535571A1 (de) * 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
DE69726571T2 (de) * 1997-09-01 2004-11-04 Aventis Pharma Deutschland Gmbh Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster

Also Published As

Publication number Publication date
CN1346369B (zh) 2011-09-28
HUP0103920A3 (en) 2006-04-28
SI1123313T1 (sl) 2007-06-30
HUP0103920A2 (hu) 2002-02-28
IL196645A (en) 2012-08-30
CA2345882A1 (en) 2000-05-04
AU1124100A (en) 2000-05-15
ATE355303T1 (de) 2006-03-15
EP1813624A1 (en) 2007-08-01
AU774989B2 (en) 2004-07-15
SI1813624T1 (sl) 2010-12-31
PT1813624E (pt) 2010-10-27
DK1123313T3 (da) 2007-06-18
EP1123313A2 (en) 2001-08-16
HU228492B1 (en) 2013-03-28
PT1123313E (pt) 2007-04-30
IL142334A (en) 2010-04-29
JP2002528465A (ja) 2002-09-03
HK1040944A1 (en) 2002-06-28
WO2000024893A3 (en) 2000-09-14
WO2000024893A2 (en) 2000-05-04
ATE477270T1 (de) 2010-08-15
CY1107584T1 (el) 2013-03-13
DE69935345T3 (de) 2018-03-01
ES2283139T5 (es) 2018-03-05
TWI234583B (en) 2005-06-21
EP1813624B1 (en) 2010-08-11
EP1123313B2 (en) 2018-01-10
AR020848A1 (es) 2002-05-29
DE69935345T2 (de) 2007-07-05
HK1040944B (zh) 2007-09-07
JP2010248207A (ja) 2010-11-04
JP5558213B2 (ja) 2014-07-23
CN101703760A (zh) 2010-05-12
JP4809977B2 (ja) 2011-11-09
KR20010075661A (ko) 2001-08-09
EP1123313B1 (en) 2007-02-28
DK1813624T3 (da) 2010-11-22
CN1346369A (zh) 2002-04-24
ES2347884T3 (es) 2010-11-22
DE69935345D1 (de) 2007-04-12
CA2345882C (en) 2011-02-01
DE69942680D1 (de) 2010-09-23
ES2283139T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
CY1110801T1 (el) Μεθοδοι και συνθεσεις για την προληψη και θεραπεια της αναιμιας
CY1108154T1 (el) Μεθοδοι καi συνθεσεις για την προληψη και τη θεραπεiα της αναιμιας
RS20090086A (en) Nucleoside analogs with carobxamidine modified monocyclic base
DK395689D0 (da) Pharmaceutisk tilberedning til behandling af diabetes mellitus
MX9204861A (es) Analogos de polipeptidos que tienen actividad liberadora de la hormona de crecimiento.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
DE60000288D1 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
PT809512E (pt) Solucoes farmaceuticas salinas nao inorganicas para administracao endonasal de uma calcitonina
IT1187687B (it) Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
IT1187828B (it) Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
ATE239474T1 (de) Verwendung von levobupivacain
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
NO911022D0 (no) Fremgangsmaate og preparat for oeket hudkonsentrasjon av aktive bestanddeler ved iontoforese.